CAP-1002 is a cardiac cell therapy that is currently being investigated in clinical trials for the use of Duchenne muscular dystrophy (DMD)-related cardiomyopathy.
The therapy consists of allogenic cardiosphere-derived cells (CDCs), meaning it’s produced in a laboratory using heart tissue from a healthy donor and stored until required. When needed, it’s administered via infusion into a coronary artery.
Studies of CAP-1002 in mouse models found that the therapy could improve heart function and increase exercise tolerance. It also slowed down inflammation, scarring and oxidative stress on the heart. The current clinical trial is being conducted with 25 males with Duchenne MD and the six-month results were published in April where it was found to be safe and well tolerated. Those who had the therapy showed improvement in some cardiac and upper limb function tests compared to the control group. Find out more about CAP-1002 here.
Muscular Dystrophy News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?